All | Male | Female | HLA-B27-negative | HLA-B27-positive | No concomitant DMARD at baseline | Concomitant DMARD at baseline | |
---|---|---|---|---|---|---|---|
Median First quartile, third quartile [95% confidence interval] | |||||||
Patients with enthesitis, MASES ≥ 1 at baseline | |||||||
MASES: 0 to 13, number (percentage) | 667 (100) | 431 (64.6) | 236 (35.4) | 126 (18.9)a | 523 (78.4)a | 499 (74.8) | 168 (25.2) |
Baseline | 5 2, 8 | 4 2, 7 | 7 4, 9 | 5 2, 9 | 5 2, 8 | 5 2, 8 | 4 2, 8 |
Week 12 | 1 0, 4 | 0 0, 2 | 1 0, 5 | 1 0, 5 | 0 0, 3 | 0 0, 3 | 1 0, 4 |
Change from baseline to week 12 | -2 -5,-1 [-3 to -2] | -2 -5,-1 [-3 to -2] | -3 -6,-1 [-4 to -2] | -2 -5,-1 [-3 to -2] | -3 -6,-1 [-3 to -2] | -3 -5,-1 [-3 to -2] | -2 -5,-1 [-5 to -2] |
Patients with peripheral arthritis, SJC ≥ 1 at baseline | |||||||
TJC: 0 to 46, number (percentage) | 281 (100) | 175 (62.2) | 106 (37.7) | 57 (20.3)a | 217 (77.2)a | 170 (60.5) | 111 (39.5) |
Baseline | 5 2, 12 | 4 2, 10 | 7 3, 14 | 6 3, 13 | 5 2, 12 | 4 2, 10 | 6 3, 13 |
Week 12 | 1 0, 3 | 1 0, 3 | 1 0, 4 | 1 0, 4 | 0 0, 3 | 0 0, 3 | 1 0, 4 |
Change from baseline to week 12 | -3 -8,-1 [-4 to -2] | -2 -6,-1 [-3 to -2] | -4 -10,-2 [-6 to -3] | -3 -10,-1 [-6 to -2] | -3 -7,-1 [-4 to -2] | -2 -7,-1 [-3 to -2] | -3 -9,-2 [-4 to -2] |
SJC: 0 to 44, number (percentage) | 281 (100) | 175 (62.2) | 106 (37.7) | 57 (20.3)a | 217 (77.2)a | 170 (60.5) | 111 (39.5) |
Baseline | 2 1, 4 | 2 1, 3 | 2 1, 6 | 2 1, 6 | 2 1, 4 | 2 1, 3 | 2 1, 6 |
Week 12 | 0 0, 1 | 0 0, 1 | 0 0, 1 | 0 0, 1 | 0 0, 1 | 0 0, 1 | 0 0, 1 |
Change from baseline to week 12 | -1 -3,-1 [-2 to -1] | -1 -3,-1 [-2 to -1] | -2 -4,-1 [-2 to -1] | -1 -4,-1 [-2 to -1] | -1 -3,-1 [-2 to -1] | -1 -2,-1 [-1 to -1] | -2 -4,-1 [-2 to -2] |